Catalyst event

Recursion Pharmaceauticals Inc (RXRX)

From KEDI U.S. Medical AI Index (KUSMAI)

Q2 2026 earnings release with analysts forecasting an EPS of approximately -$0.24; as earnings releases typically cause significant price volatility, a medium importance is expected.

Korean translation

2026년 2분기 실적 발표 및 분석가들의 주당순이익(EPS) 약 -0.24달러 전망; 실적 발표는 통상적으로 큰 가격 변동성을 동반하므로 'Medium' 중요도가 예상됨.